UNSPSC 51144007: Dexmethylphenidate hydrochloride

This classification denotes a cns stimulant with the molecular formula C14H19NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1678OK0E08, chemically known as 2-piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (r-(r*,r*))- but more generally known as dexmethylphenidate hydrochloride, which bears US NIH Compound Identifier 154100. European Medicines Agency schedules Dexmethylphenidate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20614.

UNSPSC 51144007 Dexmethylphenidate hydrochloride is a Commodity-level code that captures pharmaceutical products and controlled substances procured by state and local health agencies, corrections departments, and cooperative purchasing alliances. Recent solicitations under this code reflect state and local demand for generic pharmaceuticals, naloxone and drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The work spans procurement of naloxone for community health initiatives, generic multi-source pharmaceuticals for distribution across government facilities, and exploration of direct contracting models between state agencies and pharmaceutical manufacturers to bypass traditional pharmacy benefit managers and wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries and an initial two-year contract term plus optional one-year renewal; the bid deadline was July 26, 2023, with electronic submission required through the county's e-Procurement Portal and FEMA funding compliance required. The Texas HHS Commission released RFI HHS0017013 on April 3, 2026, as preliminary market intelligence gathering on direct-to-manufacturer prescription programs and vendor capacity for establishing direct contracts with self-insured employers and state agencies outside traditional PBM and wholesaler arrangements. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon; proposals were due March 26, 2026, with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness and the remainder on fixed pricing, administrative fee compliance, EDI capability, and administrative fee acceptance.